Medscape is reporting that the FDA has issued a "reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, including golimumab (Simponi, Centocor Ortho-Biotech Inc)."

The reminder was issued because " histoplasmosis and other invasive fungal infections are not consistently recognized in patients taking TNF-a blockers including Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab)."

To read the full article at Medscape Rheumatology News, please click here.

STAY INFORMED! Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!